Back to Gene
GBE1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GBE1 gene

The GBE1 gene provides instructions for making the glycogen branching enzyme, which is essential for the proper structure and storage of glycogen in the body.

Normal Function

The GBE1 gene provides instructions for making the glycogen branching enzyme. This enzyme is involved in the last step of the production of a complex sugar called glycogen, which is a major source of stored energy in the body. Glycogen is made up of many molecules of a simple sugar called glucose; some glucose molecules are linked together in a straight line, while others branch off the main line and form side chains. The glycogen branching enzyme is involved in the formation of these side chains. The branched structure of glycogen makes it more compact for storage and allows it to break down more easily when it is needed for fuel.

Health Conditions Related to Genetic Changes

Adult polyglucosan body disease

At least three mutations in the GBE1 gene have been found to cause adult polyglucosan body disease, a condition that affects the nervous system. These mutations change single protein building blocks (amino acids) in the glycogen branching enzyme. One mutation appears to be more common in affected people with Ashkenazi Jewish ancestry. This mutation replaces the amino acid tyrosine with the amino acid serine at position 329 in the enzyme (written Tyr329Ser or Y329S).

Most mutations that cause adult polyglucosan body disease lead to a shortage (deficiency) of the enzyme. As a result, glycogen has fewer side chains. These abnormal glycogen molecules, called polyglucosan bodies, accumulate within cells and cause damage. Nerve cells (neurons) appear to be particularly vulnerable to the accumulation of polyglucosan bodies in this disorder. Damage to neurons causes reduced sensation, weakness, and other nervous system problems in people with adult polyglucosan body disease.

Glycogen storage disease type IV

Approximately 40 mutations in the GBE1 gene have been found to cause glycogen storage disease type IV (GSD IV). This disorder is characterized by liver and muscle problems that usually begin in infancy and are caused by a buildup of abnormal glycogen. Most of the mutations that cause this condition change single amino acids in the glycogen branching enzyme.

The GBE1 gene mutations that cause GSD IV lead to a severe shortage or complete absence of glycogen branching enzyme. As a result, polyglucosan bodies accumulate in cells, leading to damage and cell death. Polyglucosan bodies build up in cells throughout the body, but liver cells and muscle cells are most severely affected in GSD IV. Glycogen accumulation in the liver interferes with liver functioning, causing an enlarged liver and liver disease. The inability of muscle cells to break down glycogen for energy leads to muscle weakness and wasting.

It is unclear why liver and muscle cells are affected by the accumulation of polyglucosan bodies in GSD IV, while neurons are solely affected in adult polyglucosan body disease.

Other Names for This Gene

  • amylo-(1,4 to 1,6) transglucosidase
  • amylo-(1,4 to 1,6) transglycosylase
  • GBE
  • GLGB_HUMAN
  • glucan (1,4-alpha-), branching enzyme 1
  • glycogen branching enzyme

Frequently Asked Questions

Early symptoms often include progressive weakness or stiffness in the legs, difficulty walking, urinary urgency or incontinence, and mild cognitive changes. Some patients notice a gradual loss of fine motor skills or develop peripheral neuropathy that feels like tingling or numbness.
Diagnosis usually starts with clinical evaluation and MRI showing characteristic white‑matter changes. Genetic testing—either a targeted GBE1 panel or whole‑exome sequencing—identifies pathogenic variants. In some labs, enzyme activity can be measured in fibroblasts or leukocytes to support the genetic result.
Carrier testing can be done for a partner, and if both are carriers, options include prenatal diagnosis via chorionic villus sampling or amniocentesis, pre‑implantation genetic testing (PGT‑M) with IVF, or using donor gametes. Genetic counseling is recommended to discuss risks and personal preferences.
No cure exists yet, but supportive care helps. Physical therapy and regular aerobic exercise can maintain mobility; bladder training and medications may improve urinary symptoms. Some clinicians use low‑glycemic diets to reduce glycogen load, though evidence is limited. Research into enzyme‑replacement and gene‑therapy is ongoing, so staying in touch with a specialty center is advisable.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA